Relay Therapeutics Q2 Revenue Misses by 60%, Loss Widens on Surging R&D Costs
RLAY has more than doubled off its 52-week low of $3.025.
Summary
Relay Therapeutics reported a sharp Q2 miss, with revenue of just $350K against an $872.73K consensus—a 60% shortfall—while net loss widened to $83.71M, well above the $74.20M estimate. The miss was driven by a jump in R&D spending tied to the zovegalisib clinical program, plus higher legal costs. This follows the May 2026 positive Phase 2 data and a $316M public offering that boosted cash to $911M, extending the runway into 2029. The company now expects to start a Phase 3 trial in 1L breast cancer in early 2027, with a key enrollment update for the ongoing ReDiscover-2 trial in 2L breast cancer due by year-end 2026. The revenue miss and cost overruns raise questions about burn rate and execution, even with a strong cash position. The upcoming ReDiscover-2 update will be a critical catalyst for the stock.
At the time of this announcement, RLAY was trading at $19.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $3.03 to $20.79. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.